Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-κB activity

Journal of Bone and Mineral Research

Volumn 19, Issue 11, 2004, Pages 1905-1916

  Yip, Kirk Ho Man ^a   Zheng, Ming H ^a   Hao, Tian Feng ^a   Steer, James H ^b   Joyce, David A ^b   Xu, Jiake ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Lipopolysaccharide; NF B; Osteoclast; Osteolysis; Parthenolide; RANKL

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; OSTEOCLAST DIFFERENTIATION FACTOR; PARTHENOLIDE; SESQUITERPENE LACTONE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; CELL RECEPTOR; GLYCOPROTEIN; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 1; LACTONE; LIPOPOLYSACCHARIDE; LUCIFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPROTEGERIN; SESQUITERPENE; TNFRSF11B PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANTIMICROBIAL ACTIVITY; APOPTOSIS; ARTICLE; BONE DESTRUCTION; CALVARIA; CELL DEATH; CELL DIFFERENTIATION; CELL PROTECTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; MEDICAL ASSESSMENT; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ACTIVE TRANSPORT; ANIMAL; BONE; C57BL MOUSE; DOSE RESPONSE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; MACROPHAGE; METABOLISM; PROTEIN TRANSPORT; REPORTER GENE; TIME; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BLOTTING, WESTERN; BONE AND BONES; BONE RESORPTION; CELL DIFFERENTIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENES, REPORTER; GLYCOPROTEINS; GREEN FLUORESCENT PROTEINS; INTERLEUKIN-1; LACTONES; LIPOPOLYSACCHARIDES; LUCIFERASES; MACROPHAGES; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; NF-KAPPA B; OSTEOCLASTS; OSTEOLYSIS; OSTEOPROTEGERIN; PROTEIN TRANSPORT; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SESQUITERPENES; TIME FACTORS; TNF RECEPTOR-ASSOCIATED FACTOR 6; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 16644376048     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.040919     Document Type: Article

References (43)

1. Nair SP, Meghji S, Wilson M, Reddi K, White P, Henderson B 1996 Bacterially induced bone destruction: Mechanisms and misconceptions. Infect Immun 64:2371-2380.
2. Hara Y, Ukai T, Yoshimura A, Shiku H, Kato I 1998 Histopathological study of the role of CD4- and CD8-positive T cells on bone resorption induced by Escherichia coli endotoxin. Calcif Tissue Int 63:63-66.
3. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B 1998 Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 282:2085-2088.
4. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, Gros P, Malo D 1999 Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 189:615-625.
5. Shuto T, Jimi E, Kukita T, Hirata M, Koga T 1994 Granulocyte-macrophage colony stimulating factor suppresses lipopolysaccharide-induced osteoclast-like cell formation in mouse bone marrow cultures. Endocrinology 134:831-837.
6. Abu-Amer Y, Ross FP, Edwards J, Teitelbaum SL 1997 Lipopolysaccharide- stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest 100:1557-1565.
7. Takami M, Kim N, Rho J, Choi Y 2002 Stimulation by toll-like receptors inhibits osteoclast differentiation. J Immunol 169:1516-1523.
8. Hou L, Sasaki H, Stashenko P 2000 Toll-like receptor 4-deficient mice have reduced bone destruction following mixed anaerobic infection. Infect Immun 68:4681-4687.
9. Hall IH, Starnes CO Jr, Lee KH, Waddell TG 1980 Mode of action of sesquiterpene lactones as anti-inflammatory agents. J Pharmacol Sci 69:537-543.
10. Heinrich M, Robles M, West JE, Ortiz de Montellano BR, Rodriguez E 1998 Ethnopharmacology of Mexican asteraceae (Compositae). Annu Rev Pharmacol Toxicol 38:539-565.
11. Schinella GR, Giner RM, Recio MC, Mordujovich de Buschiazzo P, Rios JL, Manez S 1998 Anti-inflammatory effects of South American Tanacetum vulgare. J Pharm Pharmacol 50:1069-1074.
12. Bork PM, Schmitz ML, Kuhnt M, Escher C, Heinrich M 1997 Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappaB. FEBS Lett 402:85-90.
13. Hehner SP, Hofmann TG, Droge W, Schmitz ML 1999 The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J Immunol 163:5617-5623.
14. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet RJ Jr, Sledge GW Jr, Nakshatri H 2000 Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19:4159-4169.
15. Sheehan M, Wong HR, Hake PW, Malhotra V, O'Connor M, Zingarelli B 2002 Parthenolide, an inhibitor of the nuclear factor-kappaB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol Pharmacol 61:953-963.
16. Lopez-Franco O, Suzuki Y, Sanjuan G, Blanco J, Hernandez-Vargas P, Yo Y, Kopp J, Egido J, Gomez-Guerrero C 2002 Nuclear factor-kappa B inhibitors as potential novel antiinflammatory agents for the treatment of immune glomerulonephritis. Am J Pathol 161:1497-1505.
17. Xu J, Tan JW, Huang L, Gao XH, Laird R, Liu D, Wysocki S, Zheng MH 2000 Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand. J Bone Miner Res 15:2178-2186.
18. Schmid JA, Birbach A, Hofer-Warbinek R, Pengg M, Burner U, Furtmuller PG, Binder BR, de Martin R 2000 Dynamics of NF kappa B and Ikappa Balpha studied with green fluorescent protein (GFP) fusion proteins. Investigation of GFP-p65 binding to DNa by fluorescence resonance energy transfer. J Biol Chem 275:17035-17042.
19. Wang C, Steer JH, Joyce DA, Yip KHM, Zheng MH, Xu J 2003 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclaslogenesis by suppressing RANKL-induced NF-kB activation. J Bone Miner Res 18:2159-2168.
20. Xu J, Feng HT, Wang C, Yip KH, Pavlos N, Papadimitriou JM, Wood D, Zheng MH 2003 Effects of Bafilomycin A1: An inhibitor of vacuolar H (+)-ATPases on endocytosis and apoptosis in RAW cells and RAW cell-derived osteoclasts. J Cell Biochem 88:1256-1264.
21. Li YC, Ross J, Scheppler JA, Franza BR Jr 1991 An in vitro transcription analysis of early responses of the human immunodeficiency virus type I long terminal repeat to different transcriptional activators. Mol Cell Biol 11:1883-1893.
22. Steer JH, Kroeger KM, Abraham LJ, Joyce DA 2000 Glucocorticoids suppress tumor necrosis factor-alpha expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-kappa B and c-Jun-activating transcription factor-2 binding sites in the promoter. J Biol Chem 275:18432-18440.
23. Zou W, Bar-Shavit Z 2002 Dual modulation of osteoclast differentiation by lipopolysaccharide. J Bone Miner Res 17:1211-1218.
24. Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, Yamamoto A, Pando MP, Asano T, Verma IM, Oda H, Nakamura K, Tanaka S 2000 Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol 148:333-342.
25. Itoh K, Udagawa N, Katagiri T, Iemura S, Ueno N, Yasuda H, Higashio K, Quinn JM, Gillespie MT, Martin TJ, Suda T, Takahashi N 2001 Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. Endocrinology 142:3656-3662.
26. Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V, Schulze-Osthoff K, Droge W, Schmitz ML 1998 Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem 273:1288-1297.
27. Schmidt TJ 1997 Helenanolide-type sesquiterpene lactones-III. Rates and stereochemistry in the reaction of helenalin and related helenanolides with sulfhydryl containing biomolecules. Bioorg Med Chem 5:645-653.
28. Dupuis G, Mitchell JC, Towers GH 1974 Reaction of alantolactone, an allergenic sesquiterpene lactone, with some amino acids. Resultant loss of immunologic reaclivity. Can J Biochem 52:575-581.
29. Garcia-Pineres AJ, Castro V, Mora G, Schmidt TJ, Strunck E, Pahl HL, Merfort I 2001 Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J Biol Chem 276:39713-39720.
30. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM 2001 The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 8:759-766.
31. Shirakawa F, Saito K, Bonagura CA, Galson DL, Fenton MJ, Webb AC, Auron PE 1993 The human prointerleukin 1 beta gene requires DNA sequences both proximal and distal to the transcription start site for tissue-specific induction. Mol Cell Biol 13:1332-1344.
32. Kunsch C, Rosen CA 1993 NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol 13:6137-6146.
33. Libermann TA, Baltimore D 1990 Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 10:2327-2334.
34. Drouet C, Shakhov AN, Jongeneel CV 1991 Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor-alpha promoter in primary macrophages. J Immunol 147:1694-700.
35. Oeth PA, Parry GC, Kunsch C, Nantermet P, Rosen CA, Mackman N 1994 Lipopolysaccharide induction of tissue factor gene expression in monocytic cells is mediated by binding of c-Rel/p65 heterodimers to a kappa B-like site. Mol Cell Biol 14:3772-3781.
36. Eck SL, Perkins ND, Carr DP, Nabel GJ 1993 Inhibition of phorbol ester-induced cellular adhesion by competitive binding of NF-kappa B in vivo. Mol Cell Biol 13:6530-6536.
37. Chiang CY, Kyritsis G, Graves DT, Amar S 1999 Interleukin-1 and tumor necrosis factor activities partially account for calvarial bone resorption induced by local injection of lipopolysaccharide. Infect Immun 67:4231-4236.
38. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL 2000 TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:1481-1488.
39. Jiang Y, Mehta CK, Hsu TY, Alsulaimani FF 2002 Bacteria induce osteoclastogenesis via an osteoblast-independent pathway. Infect Immun 70:3143-3148.
40. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U 1997 Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11:3482-3496.
41. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R 1997 Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 3:1285-1289.
42. Rogers MJ, Chilton KM, Coxon FP, Lawry J, Smith MO, Suri S, Russell RG 1996 Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res 11:1482-1491.
43. Wen J, You KR, Lee SY, Song CH, Kim DG 2002 Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem 277:38954-38964.